Therapeutic applications of P53 isoforms in regenerative medicine, aging and cancer
US-9068165-B2 · Jun 30, 2015 · US
Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
US9944927B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9944927-B2 |
| Application number | US-201514754000-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2015 |
| Priority date | Nov 12, 2007 |
| Publication date | Apr 17, 2018 |
| Grant date | Apr 17, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of enhancing immune cell function of a population of T cells having an endogenous wildtype p53 gene, the method comprising introducing into the population of T cells an agent that activates the function or expression of Δ133p53, wherein the agent comprises a polynucleotide encoding Δ133p53 or an expression cassette comprising a polynucleotide sequence encoding Δ133p53. 2. The method of claim 1 , wherein the population of T cells is a mammalian T cell population. 3. The method of claim 2 , wherein the mammalian T cell population is a human T cell population. 4. The method of claim 1 , wherein the population of T cells comprises CD8+ T cells.
Assignees
Inventors
Classifications
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title
Stem-loop; Hairpin · CPC title
- C12N15/113Primary
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title
against oncogenes or tumor suppressor genes · CPC title
interfering nucleic acids [NA] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9944927B2 cover?
- The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation.
- Who is the assignee on this patent?
- The Us Secretary Of The Department Of Health And Human Services, The Univ Of Dundee, Masaryk Memorial Cancer Inst, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C12N15/113. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).